Literature DB >> 6379857

Polymorphonuclear leucocytes defective in oxidative metabolism inhibit in vitro growth of Plasmodium falciparum. Evidence against an oxygen-dependent mechanism.

A Kharazmi, S Jepsen, N H Valerius.   

Abstract

This report presents evidence that polymorphonuclear leucocytes (PMN) from chronic granulomatous disease (CGD) patients, who are defective in oxidative metabolism, are capable of inhibiting in vitro multiplication of Plasmodium falciparum. Using a microtitre in vitro inhibition assay, we incubated various numbers of peripheral blood neutrophils from CGD patients and from normal individuals with P. falciparum isolate F32 in the in vitro culture system. Inhibition of parasite growth by neutrophils was determined after 48 h of culture. At PMN to erythrocyte ratio of 1:50 there was an inhibition of parasite growth of 57% by normal neutrophils and 39% to 68% by CGD cells. When the neutrophils were stimulated by phorbol myristate acetate, both cell types enhanced inhibition of parasite growth. These findings indicate that the oxygen-independent systems of human neutrophils are involved in parasite destruction. Constituents of neutrophil granules such as acid hydrolases, lactoferrin, and cationic proteins could be regarded as potential mediators of parasite destruction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379857     DOI: 10.1111/j.1365-3083.1984.tb00981.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  12 in total

1.  Reassessment of the role of splenic leukocyte oxidative activity and macrophage activation in expression of immunity to malaria.

Authors:  L A Cavacini; M Guidotti; L A Parke; J Melancon-Kaplan; W P Weidanz
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

2.  Effect of monodesethyl amodiaquine on human polymorphonuclear neutrophil functions in vitro.

Authors:  M T Labro; J el Benna
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum.

Authors:  Stephanie Kapelski; Torsten Klockenbring; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  J Leukoc Biol       Date:  2014-08-12       Impact factor: 4.962

4.  Phagocyte-derived reactive oxygen species do not influence the progression of murine blood-stage malaria infections.

Authors:  S M Potter; A J Mitchell; W B Cowden; L A Sanni; M Dinauer; J B de Haan; N H Hunt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Tumor necrosis factor enhances neutrophil-mediated killing of Plasmodium falciparum.

Authors:  L M Kumaratilake; A Ferrante; C M Rzepczyk
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

6.  In vitro effect of fansimef on human neutrophil and monocyte function.

Authors:  A Kharazmi; H Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Resolution of acute malarial infections by T cell-dependent non-antibody-mediated mechanisms of immunity.

Authors:  L A Cavacini; L A Parke; W P Weidanz
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

8.  Tumor necrosis factor primes neutrophils to kill Staphylococcus aureus by an oxygen-dependent mechanism and Plasmodium falciparum by an oxygen-independent mechanism.

Authors:  I C Kowanko; A Ferrante; G Clemente; L M Kumaratilake
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 9.  A bite to fight: front-line innate immune defenses against malaria parasites.

Authors:  Stephanie Tannous; Esther Ghanem
Journal:  Pathog Glob Health       Date:  2018-01-29       Impact factor: 2.894

10.  Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice.

Authors:  Miranda S Oakley; Victoria Majam; Babita Mahajan; Noel Gerald; Vivek Anantharaman; Jerrold M Ward; Lawrence J Faucette; Thomas F McCutchan; Hong Zheng; Masaki Terabe; Jay A Berzofsky; L Aravind; Sanjai Kumar
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.